share_log

复宏汉霖(02696.HK):HLX53联合汉斯状 及汉贝泰一线治疗局部晚期或转移性肝细胞癌的临床试验申请获国家药监局批准

Fu Hong Han Lin (02696.HK): A clinical trial application for HLX53 combined with Hans-type and Hanbeitai for first-line treatment of locally advanced or metastatic hepatocellular carcinoma was approved by the State Drug Administration

Gelonghui Finance ·  Apr 17 04:59

Gelonghui, April 17 | Fu Hong Han Lin (02696.HK) issued an announcement. Recently, HLX53 (anti-Tigit FC fusion protein) (“HLX53”) in combination with Hans form (slulizumab injection) (“Hans form ”) and Hambetai (bevacizumab injection) (“Hambetai””) Clinical trial applications for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC) were approved by the National Drug Administration (“NMPA”). The company plans to conduct phase 2 clinical trials of this treatment plan in China (excluding Hong Kong, Macao and Taiwan regions, same below) when conditions are met.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment